Strides Pharma Science, in a stock exchange filing on April 6, disclosed the outcomes of a routine inspection conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of its wholly owned subsidiary, Strides Alathur Private Limited, situated in Chennai's Alathur.
The pharma company said the inspection was conducted from April 1-5.
According to the filing, the inspection concluded with the issuance of two observations by the USFDA.
Strides Pharma has pledged to address these observations within the stipulated timeframe.
The company has said the stock exchanges will be informed of any further developments related to this matter.
At the end of the last trading session on April 5, Strides Pharma Science settled at Rs 846.90 apiece at the BSE, which was 2.22 percent higher (or Rs 18.40) as against the previous day's close.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
